Certificate library
CJC-1295 (No DAC) + Ipamorelin Certificate of Analysis
- Ozcanium
- 99.16%
- Independent · 27 Aug 2026
- Current batch
- 99.08%
- APL-CJCIP10-2608-03
- Batches published
- 3
- Measured purity
- 99.08% – 99.56%
- Most recent analysis
- 15 August 2026
Independent verification
CJC-1295 (No DAC) + Ipamorelin is independently verified by Ozcanium Analytics, an independent Australian laboratory, at 99.16% purity by UPLC-MS/MS, analysed 27 August 2026 on lot APL-CJCIP10-2608-01, net content Ipamorelin 5.10 mg, CJC-1295 (No DAC) 5.29 mg, verification code OZ-HPLCMS-JKJ2; bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL, analysed 28 August 2026, verification code OZ-ENDOTX-TPA1.
Issued by Ozcanium Analytics. Covers every vial size of this compound; each report opens as the laboratory issued it.
- Third-Party Purity COA (PDF, opens in a new tab)99.16% purity by UPLC-MS/MS · net content Ipamorelin 5.10 mg, CJC-1295 (No DAC) 5.29 mg
- Third-Party Endotoxin Test (PDF, opens in a new tab)Bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL
Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.
CJC-1295 (No DAC) + Ipamorelin is independently verified by Ozcanium Analytics at 99.16% purity by UPLC-MS/MS, analysed 27 August 2026. Every batch of CJC-1295 (No DAC) + Ipamorelin is also assayed in our own laboratory before it is released. Purity is measured by HPLC / Mass Spectrometry on the PDA 214 nm channel, reported as the combined area of every assigned component peak against all integrated impurity peaks. Each of the 2 components is identified separately by LC-MS across 5 monitored ion channels in total, and each is assigned to its own peak on the shared chromatogram. The release specification is ≥98.0% combined. Across the 3 batches published here, measured purity spans 99.08% – 99.56%.
Current batch — APL-CJCIP10-2608-03
View the full certificate- Document ID
- APL-COA-CJCIP10-2608-03
- Net content
- 10.07 mg
- Tested
- 15 August 2026
- Method
- HPLC / Mass Spectrometry
| Test | Specification | Result | Status |
|---|---|---|---|
| Appearance | White/Off-White Lyophilised Powder | Conforms | PASS |
| Identity (MS) | All components confirmed | Confirmed | PASS |
| Purity (HPLC) | ≥98.0% combined | 99.08% | PASS |
| Total Peptide Content | 95–105% | 99.0% | PASS |
| Endotoxins | <0.5 EU/mg | <0.25 EU/mg | PASS |
| # | Time (min) | Area | % Area | Assignment |
|---|---|---|---|---|
| 1 | 3.580 | 2,876,616 | 39.950 | Ipamorelin |
| 2 | 3.640 | 17,280 | 0.240 | — |
| 3 | 4.080 | 4,257,144 | 59.130 | CJC-1295 (No DAC) |
| 4 | 4.310 | 25,920 | 0.360 | — |
| 5 | 4.650 | 14,400 | 0.200 | — |
| 6 | 5.870 | 8,640 | 0.120 | — |
Every published CJC-1295 (No DAC) + Ipamorelin batch
Match the batch number printed on your vial to open its certificate.
| Batch | Size | Tested | Purity | Certificate |
|---|---|---|---|---|
| APL-CJCIP10-2608-03 | 10 mg | 15 August 2026 | 99.08% | View |
| APL-CJCIP10-2607-02 | 10 mg | 17 July 2026 | 99.56% | View |
| APL-CJCIP10-2606-01 | 10 mg | 17 June 2026 | 99.33% | View |
Earlier batches in full
APL-CJCIP10-2607-0299.56% purity tested 17 July 2026
- Document ID
- APL-COA-CJCIP10-2607-02
- Net content
- 10.03 mg
- Tested
- 17 July 2026
- Method
- HPLC / Mass Spectrometry
| Test | Specification | Result | Status |
|---|---|---|---|
| Appearance | White/Off-White Lyophilised Powder | Conforms | PASS |
| Identity (MS) | All components confirmed | Confirmed | PASS |
| Purity (HPLC) | ≥98.0% combined | 99.56% | PASS |
| Total Peptide Content | 95–105% | 99.4% | PASS |
| Endotoxins | <0.5 EU/mg | <0.25 EU/mg | PASS |
| # | Time (min) | Area | % Area | Assignment |
|---|---|---|---|---|
| 1 | 3.570 | 2,947,894 | 40.610 | Ipamorelin |
| 2 | 3.634 | 9,262 | 0.130 | — |
| 3 | 4.077 | 4,278,859 | 58.950 | CJC-1295 (No DAC) |
| 4 | 4.310 | 13,395 | 0.190 | — |
| 5 | 4.652 | 4,278 | 0.060 | — |
| 6 | 5.853 | 4,260 | 0.060 | — |
APL-CJCIP10-2606-0199.33% purity tested 17 June 2026
- Document ID
- APL-COA-CJCIP10-2606-01
- Net content
- 10.00 mg
- Tested
- 17 June 2026
- Method
- HPLC / Mass Spectrometry
| Test | Specification | Result | Status |
|---|---|---|---|
| Appearance | White/Off-White Lyophilised Powder | Conforms | PASS |
| Identity (MS) | All components confirmed | Confirmed | PASS |
| Purity (HPLC) | ≥98.0% combined | 99.33% | PASS |
| Total Peptide Content | 95–105% | 99.1% | PASS |
| Endotoxins | <0.5 EU/mg | <0.15 EU/mg | PASS |
| # | Time (min) | Area | % Area | Assignment |
|---|---|---|---|---|
| 1 | 3.565 | 2,932,500 | 39.870 | Ipamorelin |
| 2 | 3.621 | 16,431 | 0.220 | — |
| 3 | 4.064 | 4,373,191 | 59.460 | CJC-1295 (No DAC) |
| 4 | 4.277 | 18,901 | 0.260 | — |
| 5 | 4.628 | 8,367 | 0.110 | — |
| 6 | 5.837 | 5,979 | 0.080 | — |
CJC-1295 (No DAC) + Ipamorelin testing — common questions
- Is CJC-1295 (No DAC) + Ipamorelin third-party tested?
- Yes. CJC-1295 (No DAC) + Ipamorelin is independently verified by Ozcanium Analytics, an independent Australian laboratory, at 99.16% purity by UPLC-MS/MS, analysed 27 August 2026 on lot APL-CJCIP10-2608-01, net content Ipamorelin 5.10 mg, CJC-1295 (No DAC) 5.29 mg, verification code OZ-HPLCMS-JKJ2; bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL, analysed 28 August 2026, verification code OZ-ENDOTX-TPA1. Both reports are published on this page as the laboratory issued them, and each verification code can be redeemed in the lab's own portal so the document is confirmed against their records rather than ours. Every batch of CJC-1295 (No DAC) + Ipamorelin is also analysed in our own laboratory and published here in full.
- What purity is the current batch of CJC-1295 (No DAC) + Ipamorelin?
- Ozcanium Analytics, an independent Australian laboratory, measured CJC-1295 (No DAC) + Ipamorelin at 99.16% by UPLC-MS/MS on 27 August 2026. In our own laboratory, batch APL-CJCIP10-2608-03, the batch currently shipping, measured 99.08% by HPLC / Mass Spectrometry, tested 15 August 2026. The release specification is ≥98.0% combined. Across the 3 batches published here, measured purity spans 99.08% – 99.56%.
- How do I find the certificate for the CJC-1295 (No DAC) + Ipamorelin vial I have?
- Each certificate reports one production batch, so match the batch number printed on your vial against the batch history on this page rather than against the compound in general. 3 batches are published: APL-CJCIP10-2608-03, APL-CJCIP10-2607-02 and APL-CJCIP10-2606-01. If the batch you hold isn't listed, email [email protected] with the compound and batch number and we'll send the document.
- What is CJC-1295 (No DAC) + Ipamorelin tested for?
- Every batch is tested for Appearance, Identity (MS), Purity (HPLC), Total Peptide Content and Endotoxins. Each result is printed beside a fixed specification — ≥98.0% combined for purity, set as house policy rather than per batch, so a batch cannot pass by having its target moved. Molecular identity is confirmed by LC-MS across 5 monitored ion channels, each component on its own.
CJC-1295 (No DAC) + Ipamorelin composition
The registry identifiers printed on every CJC-1295 (No DAC) + Ipamorelin certificate. They are what lets the compound be checked against a public record independently of anything we assert about it.
- Ipamorelin
- 5.04 mg
- CJC-1295 (No DAC)
- 5.03 mg
- Form
- Lyophilised Powder
- Presentation
- 10 mg
Next
Holding a CJC-1295 (No DAC) + Ipamorelin batch that isn't listed above? Email [email protected] with the batch number and we'll send the document. For the analytical method behind these figures, see our guide to HPLC in peptide quality control.
All products are supplied for laboratory research use only. They are not therapeutic goods and are not for human or veterinary use.